Skip to content

Treatment of the Symptomatic Sacral Perineurial Cysts

A Randomized Controlled Trial to Compare the Efficacy of Medicine Conservative Treatment and Surgical Treatment for Symptomatic Sacral Perineurial Cysts (Tarlov Cysts) and the Applied Value of Resting State Functional Magnetic Resonance Imaging (rfMRI).

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02595190
Acronym
TSSPC
Enrollment
96
Registered
2015-11-03
Start date
2015-03-31
Completion date
2020-03-31
Last updated
2015-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

Sacral perineurial cysts(Tarlov Cysts), Resting state functional magnetic resonance imaging (rfMRI), VAS, Medicine conservative treatment, Surgical treatment

Brief summary

There are very few data and analysis in the literature regarding the symptomatic sacral perineurial cysts. Most studies are case reports or small retrospective sample, which rarely more than 20 cases. There is no an consensus on the choice of treatment (medicine conservative treatment and surgical treatment) for symptomatic sacral perineurial cysts.Our aim, therefore, is to compare the efficacy of medicine conservative treatment and surgical treatment for symptomatic sacral perineurial cysts by a randomized controlled trial. Meanwhile, resting-state functional magnetic resonance imaging is used to detect the changes at pain related brain areas, which will be develop an objective method to evaluate the clinical curative effect of the two treatment options.

Interventions

PROCEDUREsacral canal cyst microscopic tamponade

sacral canal cyst microscopic tamponade treatment

DRUGgabapentin + tramadol

dose range:gabapentin 400-1200mg tid, tramadol 100-200mg bid

DEVICEresting state functional magnetic resonance imaging (rfMRI)

First time:2 days before Surgery or Drug use; Second time:3 months after Surgery or Drug use; Third time:1 year after Surgery or Drug use

Sponsors

Southwest Hospital, China
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* 1\. Diagnosed with symptomatic sacral perineurial cysts(e.g., lumbosacral or perineal pain, fecal or urinary functions change, sexual function change, lower limb radiation pain, muscle abate, paresthesia, etc) * 2\. Visual analog scale more than or equal to 4 * 3\. Signed the informed consent * 4\. Years, range 18-60 * 5\. Self-rating anxiety scale (SAS) and self-rating depression scale (SDS) scores \< 50 * 6\. No Congenital,Mental and other Nervous system diseases * 7\. No Serious Cardiac,Pulmonary,Hepatic and Nephritic disease * 8\. No history of drug allergy * 9\. No pain(including dysmenorrhea) or drug use (e.g., antipyretics,sleeping pills) within the last month * 10\. MRI finding of sacral perineurial cysts, but without any clinical symptoms, included in the negative control group * 11\. MRI finding healthy volunteers don't have sacral perineurial cysts, included in the negative control groupblank control group

Exclusion criteria

* 1\. Patients with lumbar common diseases(e.g., Lumbar disc, Lumbar spinal stenosis, Lumbar slippage, etc) * 2\. Researchers think that Patients with disease may be interference results(e.g., Spinal deformity, spine fracture, ankylosing spondylitis, spinal tuberculosis and spinal infection, spinal tumor, pelvic inflammatory disease and other disease of department of gynaecology, etc) * 3\. Patients with other nervous system diseases(e.g., cerebral tumor, neurinoma, trigeminal neuralgia,etc) * 4\. Patients with Magnetic resonance imaging contraindication ,including claustrophobic syndrome patients * 5\. Patients with recent (less than 3 years) use chemical drugs or have obvious psychological problems * 6\. In the past 2 months involved in other drugs or devices clinical trials

Design outcomes

Primary

MeasureTime frame
Visual analog scale(VAS)3year
Structure and Function connection change(e.g., increase or decrease the thickness of the cortex, or gray matter;function connection increase or decrease) at somatosensory area1year

Secondary

MeasureTime frame
Modify Japanese orthopedic association low back pain score (M-JOA)3year
Oswestry Disability Index score (DOI)3year
MacNab curative effect evaluation3year

Other

MeasureTime frame
Urine dynamics change(e.g., urinary flow rate)3year
Number of the cyst3year
Perianal electromyography change3year
Size of the cyst3year

Countries

China

Contacts

Primary Contactjiangkai lin, PhD
jklin@tmmu.edu.cn+86-13508350708
Backup Contactweihua chu, PhD
Weihua9871@163.com+86-13657648800

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026